Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Current Treatment Options in Oncology

• Publication date

  2019-08-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11864-019-0670-1PMID 31428952
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations

  2020cited by this paper
• Abstract CT039: A Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) S1609: The neuroendocrine cohort

  2019cited by this paper
• Capecitabine and temozolomide combination for treatment of high-grade well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma. Retrospective analysis.

  2019cited by this paper
• Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.

  2019cited by this paper
• CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience

  2019cited by this paper
• Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.

  2019cited by this paper
• Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study.

  2019cited by this paper
• Treatment outcomes for well differentiated grade 3 neuroendocrine tumors (NET G3).

  2018cited by this paper
• Well‐differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high‐grade (G3) cases

  2018cited by this paper
• Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms

  2018cited by this paper
• Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index

  2018cited by this paper
• First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer

  2018cited by this paper
• Pembrolizumab (P) monotherapy in patients with previously treated metastatic high grade neuroendocrine neoplasms (HG-NENs).

  2018cited by this paper
• Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis

  2018cited by this paper
• Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx).

  2018cited by this paper
• Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)

  2018cited by this paper
• Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients

  2018cited by this paper
• Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases

  2018cited by this paper
• Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms

  2018cited by this paper
• The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond.

  2018cited by this paper
• Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial

  2018cited by this paper
• Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology

  2018cited by this paper
• Everolimus in Pancreatic Neuroendocrine Carcinomas G3

  2017cited by this paper
• Whole-genome landscape of pancreatic neuroendocrine tumours

  2017cited by this paper
• Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated

  2017cited by this paper
• Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study

  2017cited by this paper
• Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors

  2017cited by this paper
• Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.

  2017cited by this paper
• Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20%

  2017cited by this paper
• The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories

  2016cited by this paper
• Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.

  2016cited by this paper
• PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

  2016cited by this paper
• Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters.

  2016cited by this paper
• Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study

  2016cited by this paper
• Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.

  2016cited by this paper
• A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas

  2016cited by this paper
• Genomic profiling to distinguish poorly differentiated neuroendocrine carcinomas arising in different sites.

  2016cited by this paper
• Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

  2016cited by this paper
• Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.

  2016cited by this paper
• Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.

  2015cited by this paper
• A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).

  2015cited by this paper
• Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas

  2015cited by this paper
• Surgical Resection Improves the Outcome of the Patients With Neuroendocrine Tumor Liver Metastases

  2015cited by this paper
• Expression Analysis of Genes Involved in DNA Repair or Synthesis in Mixed Neuroendocrine/Nonneuroendocrine Carcinomas

  2015cited by this paper
• The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms

  2015cited by this paper
• Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.

  2015cited by this paper
• Neuroendocrine tumor G3: a pancreatic well-differentiated neuroendocrine tumor with a high proliferative rate

  2015cited by this paper
• Pancreatic neuroendocrine tumors: pathologic and molecular characteristics.

  2014cited by this paper
• Management of a metastasized high grade insulinoma (G3) with refractory hypoglycemia: case report and review of the literature.

  2014cited by this paper
• Gastroenteropancreatic high‐grade neuroendocrine carcinoma

  2014cited by this paper
• Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity.

  2014cited by this paper
• Are G3 ENETS neuroendocrine neoplasms heterogeneous?

  2013cited by this paper
• Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.

  2013cited by this paper
• Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience

  2013cited by this paper
• Prolonged Clinical Benefit of Everolimus Therapy in the Management of High-Grade Pancreatic Neuroendocrine Carcinoma

  2013cited by this paper
• Colorectal Poorly Differentiated Neuroendocrine Carcinomas and Mixed Adenoneuroendocrine Carcinomas: Insights Into the Diagnostic Immunophenotype, Assessment of Methylation Profile, and Search for Prognostic Markers

  2012cited by this paper
• Everolimus for Advanced Pancreatic Neuroendocrine Tumors

  2012cited by this paper
• Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon–rectum

  2012cited by this paper
• Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors

  2012cited by this paper
• First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

  2011cited by this paper
• Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

  2011cited by this paper
• Everolimus for advanced pancreatic neuroendocrine tumors.

  2011cited by this paper
• DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

  2011cited by this paper
• Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

  2008cited by this paper
• One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

  2008cited by this paper
• Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas

  2007cited by this paper
• Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.

  2006cited by this paper
• Pathology and genetics of tumours of the digestive system

  2000cited by this paper
• ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis.

  1999cited by this paper
• Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.

  1998cited by this paper
• Prognostic factors in patients with endocrine tumours of the duodenopancreatic area

  1998cited by this paper

• Clinico-Morphological Correlations with Ki-67 and p53 Immunohistochemical Expression in High-Grade Gastrointestinal Neuroendocrine Neoplasms

  2025cites this paper
• Downstaging and R0 resection of initially unresectable metastatic well-differentiated grade-3 pancreatic neuroendocrine tumor: a case report

  2025cites this paper
• Everolimus in the Treatment of Neuroendocrine Tumors: Lights and Shadows

  2025cites this paper
• Atypical presentation and diagnosis of a metastatic grade II pancreatic neuroendocrine tumor in a 52-year-old female patient: A case report

  2025cites this paper
• Prognostic value of CT-based radiomics in grade 1–2 pancreatic neuroendocrine tumors

  2024cites this paper
• Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3

  2024cites this paper
• Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies

  2024cites this paper
• The Application of 68Ga-Somatostatin Analog and 18F-FDG PET/CT for Bone Metastasis from Neuroendocrine Tumors

  2024influential citation
• Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms.

  2024cites this paper
• Surgery for advanced neuroendocrine tumours of the small bowel: recommendations based on a consensus meeting of the European Society of Endocrine Surgeons (ESES).

  2024cites this paper
• Surgical treatment of stage IV gastroenteropancreatic neuroendocrine carcinoma: Experience and outcomes in the United States

  2023cites this paper
• NET G3 vs NEC: p53 and Rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?

  2023cites this paper
• Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms

  2023cites this paper
• Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms

  2023cites this paper
• A rare gastric lesion: diminutive, well-differentiated, Grade 3, type 3 gastric neuroendocrine tumor with extremely high ki-67 index removed en bloc under endoscopy

  2022cites this paper
• Well-Differentiated Grade 3 Neuroendocrine Tumors

  2022cites this paper
• Primary Neuroendocrine Tumors and Primary Neuroendocrine Carcinomas of the Liver: A Proposal for a Multidiscipline Definition.

  2022cites this paper
• Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies

  2022cites this paper
• Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors.

  2021cites this paper
• New Concepts in Pathology

  2021cites this paper
• Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms

  2021cites this paper
• Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors

  2020cites this paper
• Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort

  2020cites this paper
• Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors.

  2020cites this paper
• Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations

  2020cites this paper
• Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies

  2020cites this paper